Alipogene Tiparvovec for the Treatment of LPLD Patients

Withdrawn before enrolling · Phase 2

Conditions studied: LPL Deficiency

In brief

The aim of the study is to provide further confirmatory evidence of clinical benefit in LPLD patients treated with alipogene tiparvovec by assessing both the "clinical response" (as defined by a range of parameters), and "the metabolic response" (postprandial CM metabolism) in LPLD patients with and without an immunosuppressant regimen.

Key facts

Study ID

NCT02904772

Run by

UniQure Biopharma B.V.

People needed

0

Starts

2016-10-01

Expected to finish

2020-09-01

Last updated by the study team

2017-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Perelman School of Medicine at The University of Pennsylvania Translational Medicine & Human Genetics — Philadelphia, Pennsylvania, United States
• Centre hospitalier universitaire de Sherbrooke — Sherbrooke, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.